What the evidence shows
- Average total body weight loss of approximately 15–20% at 12–24 months in published cohorts, with variation by patient.
- Improvements in metabolic markers including blood pressure, lipid profiles, and glycemic control in many patients.
- Favorable safety profile compared with surgical alternatives, with serious adverse events reported in roughly 1–2% of cases in published series.
- Sustained outcomes at 3–5 years in selected patients with appropriate follow-up.
Outcomes vary by individual. No specific result is guaranteed.
Key references
- MERIT Randomized Clinical Trial (Abu Dayyeh et al., Lancet 2022)
Multicenter randomized trial of ESG vs lifestyle therapy; demonstrated greater weight loss and metabolic improvement at 52 weeks in the ESG arm with a favorable safety profile.
- Long-term ESG outcomes (5-year follow-up)
Multiple cohorts demonstrate sustained weight loss at 3-5 years in selected patients with appropriate follow-up.
- ESG vs Laparoscopic Sleeve Gastrectomy — comparative literature
Comparative studies show LSG generally produces greater average weight loss; ESG offers an incision-free, lower-risk profile in selected patients.
- ASMBS — Position statement on endoscopic bariatric therapies
ASMBS recognizes endoscopic bariatric therapies, including ESG, as appropriate options for selected patients.
- ASGE — Endoscopic bariatric and metabolic therapies
Standards and educational resources for endoscopic bariatric practice.
- FDA — Apollo Endosurgery / Apollo OverStitch device clearance
Regulatory clearance for the suturing system used in ESG.
- IFSO — Global registry and consensus statements
International outcomes and consensus on bariatric and endoscopic procedures.
Comparative perspective
ESG is not a replacement for surgical bariatric procedures and not a replacement for GLP-1 medications. Published comparative studies suggest:
- vs. Laparoscopic Sleeve Gastrectomy: LSG generally achieves greater average weight loss; ESG involves no incisions and no permanent removal of stomach tissue.
- vs. GLP-1 medications: Different mechanisms — pharmacologic vs. mechanical restriction. Some patients combine or transition between approaches under medical supervision.
- vs. intragastric balloon: ESG is durable internal suturing; balloons are temporary devices removed at six months.
See also: Sources & Verification, ESG vs GLP-1, ESG vs Gastric Sleeve.